BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sobczak M, Zyma M, Robaszkiewicz A. The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors. Cells 2020;9:E2040. [PMID: 32900001 DOI: 10.3390/cells9092040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou L, Xiang J, He Y. Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer. Environ Sci Pollut Res Int 2021. [PMID: 34370190 DOI: 10.1007/s11356-021-15852-9] [Reference Citation Analysis]
2 Guney Eskiler G, Deveci Özkan A. The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer. Mol Immunol 2021;141:280-6. [PMID: 34906906 DOI: 10.1016/j.molimm.2021.12.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pietrzak J, Gronkowska K, Robaszkiewicz A. PARP Traps Rescue the Pro-Inflammatory Response of Human Macrophages in the In Vitro Model of LPS-Induced Tolerance. Pharmaceuticals (Basel) 2021;14:170. [PMID: 33671709 DOI: 10.3390/ph14020170] [Reference Citation Analysis]
4 Olivares-González L, Velasco S, Campillo I, Salom D, González-García E, Soriano Del Castillo JM, Rodrigo R. Nutraceutical Supplementation Ameliorates Visual Function, Retinal Degeneration, and Redox Status in rd10 Mice. Antioxidants (Basel) 2021;10:1033. [PMID: 34206804 DOI: 10.3390/antiox10071033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Rosado MM, Pioli C. ADP-ribosylation in evasion, promotion and exacerbation of immune responses. Immunology 2021;164:15-30. [PMID: 33783820 DOI: 10.1111/imm.13332] [Reference Citation Analysis]